Eli Lilly to Unveil Groundbreaking Alzheimer's Research at AAIC 2026
Eli Lilly and Company (NYSE: LLY) has announced an impressive agenda for the upcoming 2026 Alzheimer's Association International Conference (AAIC), scheduled to take place from July 12 to July 15 in London. Highlighting their ongoing commitment to Alzheimer's research, Lilly will be presenting a total of 16 abstracts, which will cover a wide range of topics related to diagnostics, long-term treatment options, and patient-centered outcomes. This research reflects Lilly's extensive 35-year history in addressing Alzheimer's disease, taking significant strides toward understanding and combating this debilitating condition.
Among the notable presentations is the Developing Topics Session on July 15, focusing on new clinical evidence regarding the drug Kisunla (donanemab-azbt). This session will unveil findings from the TRAILBLAZER-ALZ 6 and TRAILBLAZER-ALZ 2 trials, which provide critical insights into the safety and efficacy of Kisunla in early symptomatic Alzheimer's patients. Attendees will explore results pertaining to long-term safety profiles, biomarker evidence, and the potential durability of clinical benefits—offering hope to those affected by this progressive disease.
Another significant topic will be presented by Dr. Samantha Burnham, who will demonstrate how P-tau217 blood biomarker assays show strong potential in identifying Alzheimer's disease pathology in cognitively unimpaired individuals. This presents an exciting alternative to the conventional and expensive amyloid positron emission tomography (PET) imaging, broadening the scope of accessible diagnostic options for early identification of Alzheimer's.
On July 13, Dr. Lars Raket will also host a Featured Research Session, tackling important methodological questions in Alzheimer's research involving external controls versus internal extrapolation in clinical trials. The methodologies discussed here can contribute to setting new standards for how long-term outcomes are measured, showcasing Lilly's commitment to scientific rigor.
Additionally, several poster presentations will cover imaging science, health economics, and real-world prescribing trends, further illustrating the extensive research undertaken by Lilly. This includes an exploration of healthcare utilization during the progression of cognitively unimpaired Alzheimer's and a multi-trial analysis of diffusion tensor imaging biomarkers related to treatment responses.
The urgency of such research becomes increasingly apparent as estimates suggest that by 2030, around 78 million people worldwide could be living with Alzheimer's disease, a significant increase from the current 55 million. As the disease progresses silently over decades, detection and treatment options must adapt to account for early-stage diagnosis, which these studies aim to support.
In summary, Eli Lilly's presentations at AAIC 2026 are not just about showcasing new data; they represent a holistic approach to combating Alzheimer's disease through innovative research, emphasizing both patient-centered outcomes and rigorous scientific methodologies. As the field evolves, Lilly's findings could play a pivotal role in advancing the standards of care for those affected by this challenging condition.
Among the notable presentations is the Developing Topics Session on July 15, focusing on new clinical evidence regarding the drug Kisunla (donanemab-azbt). This session will unveil findings from the TRAILBLAZER-ALZ 6 and TRAILBLAZER-ALZ 2 trials, which provide critical insights into the safety and efficacy of Kisunla in early symptomatic Alzheimer's patients. Attendees will explore results pertaining to long-term safety profiles, biomarker evidence, and the potential durability of clinical benefits—offering hope to those affected by this progressive disease.
Another significant topic will be presented by Dr. Samantha Burnham, who will demonstrate how P-tau217 blood biomarker assays show strong potential in identifying Alzheimer's disease pathology in cognitively unimpaired individuals. This presents an exciting alternative to the conventional and expensive amyloid positron emission tomography (PET) imaging, broadening the scope of accessible diagnostic options for early identification of Alzheimer's.
On July 13, Dr. Lars Raket will also host a Featured Research Session, tackling important methodological questions in Alzheimer's research involving external controls versus internal extrapolation in clinical trials. The methodologies discussed here can contribute to setting new standards for how long-term outcomes are measured, showcasing Lilly's commitment to scientific rigor.
Additionally, several poster presentations will cover imaging science, health economics, and real-world prescribing trends, further illustrating the extensive research undertaken by Lilly. This includes an exploration of healthcare utilization during the progression of cognitively unimpaired Alzheimer's and a multi-trial analysis of diffusion tensor imaging biomarkers related to treatment responses.
The urgency of such research becomes increasingly apparent as estimates suggest that by 2030, around 78 million people worldwide could be living with Alzheimer's disease, a significant increase from the current 55 million. As the disease progresses silently over decades, detection and treatment options must adapt to account for early-stage diagnosis, which these studies aim to support.
In summary, Eli Lilly's presentations at AAIC 2026 are not just about showcasing new data; they represent a holistic approach to combating Alzheimer's disease through innovative research, emphasizing both patient-centered outcomes and rigorous scientific methodologies. As the field evolves, Lilly's findings could play a pivotal role in advancing the standards of care for those affected by this challenging condition.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.